All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: UNIV TX MD ANDERSON
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2020
Details:
The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: University of Montreal
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2020
Details:
University of Montreal/IRICoR will conduct and finance the research program until the license is exercised. Ipsen would assume all development activities and commercialize the drug candidate globally.